All News

kidney-147499_640.png

Anti-mesangial autoantibodies in IgA nephropathy

d EurekAlert!

IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.

Read Article
Lungs ILD

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA

d MedPage Today

Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.

Read Article
ANCA, vasculitis, test

Updated AAV Treatment Recommendations

d EurekAlert!

AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). This variety can make management challenging.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Our old friend, hydroxychloroquine

d Eric Dein, MD

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article
obesity.knee_.arthritis.jpg

Metformin Reduces Osteoarthritis Risk

d MedPage Today

Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.

Read Article
SI AS SpA ACR

Spondyloarthritis Innovations

d Robert Chao, MD

The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus. https://t.co/hKFLg1sogJ https://t.co/OxnbwpWygF

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/8bEEC6gt5Z https://t.co/Toy2DxnC4S

Links:

Dr. John Cush RheumNow ( View Tweet)
Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase 3 trial of IV 200 mg qd hydrocortisone in 800 pts admitted to ICU for severe community-acquired pneumonia. Day 28 strongly favored IV Hydrocort vs PBO for mortality (6% v 12%; P=0.006), Mech ventilation (18% vs 29.5%), vasopressors (15% v 25%) https://t.co/TqxorRAuvc https://t.co/0R7kNaKgj5

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/MZJfg2lM70 https://t.co/eOkcwd4xMz

Links:

Dr. John Cush RheumNow ( View Tweet)
The Biosimilar "Buy In" Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live. https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo

Links:

Dr. John Cush RheumNow ( View Tweet)
Metformin Reduces Osteoarthritis Risk Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported. https://t.co/dmyKssbWjO https://t.co/p7lPdjYfbU

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Innovations The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it. https://t.co/3JeNeE0EO6 https://t.co/fA1B2TA2xF

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira - but adalimumab-adaz HCF wont be available in USA until July 1, 2023 https://t.co/RRjxPW5I4O https://t.co/hf6NlkGG7W

Links:

Dr. John Cush RheumNow ( View Tweet)
Polypharmacy Increased in Psoriatic Arthritis Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA. https://t.co/vispc9ei51 https://t.co/s45Nmpf46P

Links:

Dr. John Cush RheumNow ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). https://t.co/8OZqRvD1Lv https://t.co/T7dWQWc1gX

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×